Improving Memory for Sleep Treatment Content With Text Messages
Study Details
Study Description
Brief Summary
A drop off in improvement over the months and years after treatment is common. One contributor may be poor memory for the contents of treatment. This study seeks to determine whether text messages containing reminders of the content of sessions will improve treatment outcomes.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
The growth in the use of technology provides an opportunity to send reminders to participants via text messages. The early studies on text messaging interventions indicate this approach is enjoyable for participants and has positive effects across a range of domains and treatment types. Hence, this study will test whether text messages containing reminders of the content of sessions will improve treatment outcomes. Two text messaging methods will also be tested. One is to send text messages to remind participants of their goals (PUSH condition) and the second is to send text messages to remind participants to recall their goals (PULL condition). This study will be conducted within the context of an NICHD-funded Randomized Controlled Trial (grant number R01-HD071065; protocol registration ID NCT01828320). In R01-HD071065 adolescents ages 10-18 (n = 176) will receive either the Transdiagnostic Sleep and Circadian Intervention (TranS-C) or a Psychoeducation (PE). At the 6-month follow-up assessment for R01-HD071065, participants will be randomized using 3 (PUSH text messages, PULL text messages, or no text messages) x 2 (TranS-C or PE) design. At the 6-month follow-up assessment, a questionnaire will also be administered to establish baseline memory for treatment. Participants will be sent text messages once per week until they return for the 12 month follow-up assessment for R01-HD071065. At the 12 month follow-up assessment, participants will be asked to complete the same memory for treatment questionnaire completed at the 6 month follow-up assessment as well as a questionnaire evaluating the acceptability of the text message reminders. This research is a first step toward identifying whether an inexpensive and ubiquitous technology (i.e., text messaging) can improve memory for treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: PUSH text messages Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). |
Other: PUSH text messages
The intervention is designed to remind participants of treatment components.
Behavioral: TranS-C
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Behavioral: PE
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
|
| Experimental: PULL text messages Participants will be sent text messages containing information relevant to their treatment condition (i.e., TranS-C or PE). Text messages will request a response from the participant. |
Other: PULL text messages
The intervention is designed to remind participants to recall treatment components.
Behavioral: TranS-C
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Behavioral: PE
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
|
| Other: No text messages No text messages will be sent in this condition to participants in either treatment condition (i.e., TranS-C or PE). |
Behavioral: TranS-C
The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
Other Names:
Behavioral: PE
Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Total sleep time (TST) average on weeknights via Daily Sleep Diary [Measured at 6-months post-treatment]
6mo TST
- Total sleep time (TST) average on weeknights via Daily Sleep Diary [Measured at 12-months post-treatment]
12mo TST
- Average bedtime on weeknights measured via Daily Sleep Diary [Measured at 6-months post-treatment]
6mo Avg Bedtime
- Average bedtime on weeknights measured via Daily Sleep Diary [Measured at 12-months post-treatment]
12mo Avg Bedtime
- Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale [Measured at 6-months post-treatment]
6mo CME
- Morning Eveningness preference measured via Childrens Morningness Eveningness Preference Scale [Measured at 12-months post-treatment]
12mo CME
- Patient Recall of Session Contents [Change from 6-months post-treatment to 12-months post-treatment]
6-12mo Change in Patient Recall
Secondary Outcome Measures
- Sleepiness scale [Measured at 6-months post-treatment]
Embedded within the School Sleep Habits Survey
- Sleepiness scale [Measured at 12-months post-treatment]
Embedded within the School Sleep Habits Survey
- Pittsburgh Sleep Quality Index [Measured at 6-months post-treatment]
6mo PSQI
- Pittsburgh Sleep Quality Index [Measured at 12-months post-treatment]
12mo PSQI
- Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary [Measured at 6-months post-treatment]
6mo Weeknight-Weekend Differences
- Discrepancy between weeknights and weekends for Total Sleep Time, Bedtime, and Waketime via Daily Sleep Diary [Measured at 12-months post-treatment]
12mo Weeknight-Weekend Differences
- Text Message Evaluation [Measured at 12-months post-treatment]
Measure of the acceptability of receiving text messages
- Child Behavior Checklist [Measured at 6-months post-treatment]
Parent measure
- Child Behavior Checklist [Measured at 12-months post-treatment]
Parent measure
Other Outcome Measures
- Useful and Utilized Questionnaire [Measured at 6-months post-treatment]
6mo UUQ
- Useful and Utilized Questionnaire [Measured at 12-months post-treatment]
12mo UUQ
- Daily Sleep Diary [Measured at 6-months post-treatment]
total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps.
- Daily Sleep Diary [Measured at 12-months post-treatment]
total sleep time (weekend nights), weeknight bedtime, weekend risetime, total wake time (SOL+WASO) weeknights, total wake time (SOL+WASO) weekend nights, naps.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Scoring within the lowest quartile of the Children's Morningness-Eveningness Preferences Scale (CMEP; 27 or lower) and a 7-day sleep diary showing a sleep onset time of of 10:40 pm or later for 10-13 year olds, 11 pm or later for 14-16 year olds, and 11:20 pm or later for 17-18 year olds at least 3 nights per week. Must have had the current pattern of late bedtimes for the last 3 months.
-
'At risk' in one of the five health domains: emotional, behavioral, social, physical, and cognitive. Emotional risk will be operationalized as a score of 4 or above on any of the following items on the Child Depression Rating Scale: Difficulty Having Fun, Social Withdrawal, Irritability, Depressed Feelings, Excessive Weeping, or a T-score of 61 or above on the Multidimensional Anxiety Scale for Children (MASC), based on age group (10-11 years, 12-15 year, 16-19 years) using the MASC-10 Profile. Behavioral risk will be operationalized as a Sensation Seeking Scale score greater than 3.93 for males ages 10-13, greater than 3.19 for females 10-13, greater than 4.07 for males 14-18, or greater than 3.19 for females 14-18; taking ADHD medication or Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (KSADs) diagnosis of ADHD; current alcohol or substance abuse; or past alcohol or substance dependence. Social and cognitive risk will be defined as "worse" than others the teen's age in one or more social behavior from Child Behavior Checklist (CBCL) Section VI or failing one or more academic class from CBCL Section VII, respectively. Physical risk will be operationalized as a Physical Health Questionnaire-15 score of 4 or above, six or more days of school absences, or a BMI above the 85th percentile for the participant's sex and age.
-
Age between 10 and 18 and living with a parent or guardian and and attending a class/job by 9am at least 3 days per week;
-
English language fluency;
-
Able and willing to give informed assent.
Exclusion Criteria:
-
An active, progressive physical illness (e.g., cancer, respiratory disorder) or neurological degenerative disease directly related to the onset and course of the sleep disturbance;
-
Evidence from clinical diagnosis or report by youth or parent of sleep apnea, restless legs or periodic limb movements during sleep. Youth presenting with provisional diagnoses of any of these disorders (e.g., sleep apnea) will be referred for a non-study polysomnography (PSG) evaluation at the parent's discretion and will be enrolled only if the diagnosis is disconfirmed;
-
Mental retardation, autism spectrum disorder, or other significantly impairing pervasive developmental disorder. Based on previous recruitment experiences in a youth depression study, it is expected that this exclusion will be invoked very infrequently (once every few years);
-
Bipolar disorder or schizophrenia or another current Axis I disorder if there is a significant risk of harm and/or decompensation if treatment of that comorbid condition is delayed as a function of participating in any stage of this study. Otherwise, all other comorbid psychiatric conditions will be allowed to (i) to maximize representativeness and (ii) because a byproduct may be that the treatment constitutes a helpful 'transdiagnostic' treatment for youth across psychiatric disorders.
-
A medication-free group may be difficult to recruit and would likely be unrepresentative. Hence, participants will not be excluded on the basis of stable use of medications (> 4 weeks). The exception was use of hypnotics and other medications known to alter sleep (e.g., melatonin).
-
History of substance dependence in the past six months;
-
Current suicide risk sufficient to preclude treatment on an outpatient basis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University of California, Berkeley | Berkeley | California | United States | 94720 |
Sponsors and Collaborators
- University of California, Berkeley
Investigators
- Principal Investigator: Allison G Harvey, PhD, University of California, Berkeley
- Principal Investigator: Michael R Dolsen, University of California, Berkeley
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2012-02-4007_text_message